Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells $744,660.56 in Stock

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Eric Swayze sold 9,884 shares of the business’s stock in a transaction that occurred on Friday, January 16th. The shares were sold at an average price of $75.34, for a total value of $744,660.56. Following the transaction, the executive vice president directly owned 41,935 shares in the company, valued at approximately $3,159,382.90. This represents a 19.07% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Eric Swayze also recently made the following trade(s):

• On Friday, January 16th, Eric Swayze sold 49 shares of Ionis Pharmaceuticals stock. The stock was sold at an average price of $75.97, for a total value of $3,722.53.
• On Friday, January 2nd, Eric Swayze sold 23,463 shares of Ionis Pharmaceuticals stock. The stock was sold at an average price of $79.12, for a total value of $1,856,392.56.

Ionis Pharmaceuticals Stock Up 1.6%

Shares of NASDAQ IONS traded up $1.20 during midday trading on Tuesday, reaching $77.53. 4,894,343 shares of the company’s stock traded hands, compared to its average volume of 1,492,706. The company has a market cap of $12.56 billion, a price-to-earnings ratio of -45.88 and a beta of 0.28. The company has a quick ratio of 2.78, a current ratio of 2.79 and a debt-to-equity ratio of 0.96. Ionis Pharmaceuticals, Inc. has a one year low of $23.95 and a one year high of $86.15. The stock’s 50 day simple moving average is $78.90 and its 200-day simple moving average is $64.33.

Ionis Pharmaceuticals (NASDAQ:IONS) last issued its quarterly earnings results on Wednesday, October 29th. The company reported ($0.80) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.15) by $0.35. Ionis Pharmaceuticals had a negative return on equity of 44.26% and a negative net margin of 26.45%.The business had revenue of $156.72 million for the quarter, compared to the consensus estimate of $131.75 million. During the same period in the prior year, the firm posted ($0.95) earnings per share. The business’s quarterly revenue was up 17.2% on a year-over-year basis. On average, analysts predict that Ionis Pharmaceuticals, Inc. will post -3.5 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Steigerwald Gordon & Koch Inc. purchased a new stake in shares of Ionis Pharmaceuticals in the third quarter valued at approximately $25,000. Golden State Wealth Management LLC grew its stake in Ionis Pharmaceuticals by 198.4% in the 3rd quarter. Golden State Wealth Management LLC now owns 376 shares of the company’s stock valued at $25,000 after acquiring an additional 250 shares during the last quarter. Mather Group LLC. purchased a new stake in Ionis Pharmaceuticals in the 3rd quarter valued at approximately $27,000. Allworth Financial LP boosted its stake in shares of Ionis Pharmaceuticals by 231.8% during the second quarter. Allworth Financial LP now owns 740 shares of the company’s stock valued at $29,000 after acquiring an additional 517 shares during the last quarter. Finally, Quarry LP acquired a new position in shares of Ionis Pharmaceuticals in the third quarter valued at approximately $38,000. Hedge funds and other institutional investors own 93.86% of the company’s stock.

Key Headlines Impacting Ionis Pharmaceuticals

Here are the key news stories impacting Ionis Pharmaceuticals this week:

• Positive Sentiment: Analyst / media bullishness on olezarsen: A recent Seeking Alpha piece highlights an expected 2026 launch of olezarsen in SHTG and argues that approval/commercial rollout could drive a substantial revenue inflection for Ionis; the article notes strong recent momentum and positions olezarsen as the key upside catalyst. Ionis: Expected 2026 Launch Of Olezarsen In SHTG To Spur Leap In Revenue Growth
• Neutral Sentiment: Trading and technicals: Intraday volume is elevated (~4.9M shares vs. a ~1.5M average), suggesting the market is actively reacting to the news flow; the stock is above its 200‑day moving average (support) but near the 50‑day average—momentum could depend on upcoming clinical/commercial milestones.
• Negative Sentiment: Large, concentrated insider selling: Multiple executives (including CEO Brett P. Monia and several EVPs) sold shares on Jan 16 totaling roughly 117K shares (~$8.8M) — CEO sale (~44K shares, ~$3.3M) and several EVP sales of ~8–13K shares each. These filings can be reviewed in the SEC disclosures, which may signal tax/diversification activity but can also weigh on sentiment.
  Bennett filing
  Birchler filing
  Devers filing
  Hougen filing
  Jenne filing
  Kordasiewicz filing
  Monia (CEO) filing
  O’neil filing
  Schneider filing
  Swayze filings

Analysts Set New Price Targets

Several brokerages have weighed in on IONS. Needham & Company LLC increased their price target on Ionis Pharmaceuticals from $78.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, October 30th. Guggenheim upped their price target on Ionis Pharmaceuticals from $90.00 to $92.00 and gave the stock a “buy” rating in a report on Tuesday, September 23rd. TD Cowen increased their price objective on shares of Ionis Pharmaceuticals from $59.00 to $99.00 and gave the company a “buy” rating in a report on Thursday, October 30th. Oppenheimer lifted their price target on Ionis Pharmaceuticals from $84.00 to $90.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 8th. Finally, Royal Bank Of Canada boosted their target price on Ionis Pharmaceuticals from $82.00 to $95.00 and gave the stock an “outperform” rating in a report on Wednesday, December 17th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $87.05.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.